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T here is a higher incidence of brain tumours in the UK than the world average for both men (8.1 per 100,000), and 
women (5.3 per 100,000) [1]. Malignant gliomas 
are the most common primary brain tumours of 
which glioblastoma (GBM) is the most prevalent. 
GBM is also known to be the most biologically 
aggressive and cellularly heterogeneous and 
is highly diffusively infiltrative in nature which 
renders surgical excision impossible without 
causing significant neurological deficit. Typically, 
following surgery, patients undergo a course 
of radiotherapy or a combination of chemo/
radiotherapy (Stupp protocol) [2]. However, 
despite surgical debulking and improvements 
in radio- and chemotherapies, the prognosis of 
patients with GBM remains extremely poor, with 
a median survival time of only 14.5 months from 
diagnosis to death [2]. 
Particular challenges for GBM therapy 
are posed by limitations in the extent of 
feasible surgical resection, chemo- and radio-
resistance, difficulties in drug delivery across 
the blood-brain barrier (BBB, which is intact 
in tissues surrounding the tumour) and low 
drug distribution within the tumour and toxic 
effects on healthy cells. Although it is possible 
for some cytotoxic drugs to gain access to the 
major tumour mass by a virtue of damaged or 
incomplete blood-brain tumour barrier, such 
drugs fail to reach invading cancer cells which 
may be centimetres away from perceived edge of 
the tumour where the BBB is intact. 
Nanomedicine, the application of 
nanotechnology to medicine, works at the 
molecular level using engineered “bottom up” 
constructed multifunctional, spatially ordered, 
architecturally varied nanostructures (Figure 
1) to ultimately achieve medical benefit. The 
field possesses an interdisciplinary conceptual 
breath bringing together scientists and clinicians 
towards the fabrication of useful architectures, 
made up of multiple base parts each with their 
own structural or functional role driven by discrete 
molecular forces (chemical bonding, electrostatics, 
steric interactions and physical adsorption) that 
will be clinically translated. Within this nanoscale 
assemblies, specific components are included to 
tailor the particles properties such as escaping 
immune recognition, crossing of challenging 
barriers such as the BBB [3, 4], providing contrast 
in medical imaging, tumour targeting, stabilising 
the drug or biomacromolecular therapeutic, 
controlling its release, and minimising its toxicity (by 
necessitating for example lower dose and targeting 
to the desired site). Although active or passively 
targeted nanoparticulate technologies are the only 
technologies to-date to have shown promise in 
delivery across the BBB and in the treatment of 
GBM, in the field of neurosurgery and specifically 
glioma therapeutics, there is great interest, and 
much scepticism, in the rapidly developing 
application of nanopharmaceuticals [5]. 
Nanoparticle delivery and glioma 
targeting
The enhanced permeability and retention (EPR) 
phenomenon of nanoparticulate accumulation 
within tumours was first reported in the 1980’s 
while in 1995 nanoparticles were shown to 
be able to transverse the BBB (Figure 1) [6]. 
Nanoparticulate delivery systems are tailored 
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Figure 1: Schematic diagram depicting nanoparticles used in the treatment of GBM (liposomes, polymeric nanoparticles, paptide nanofibers) 
and targeting nanomedicines to GBM cells. 
in terms of their size, hydrophobicity 
and surface charge (Table 1) to facilitate 
tumour targeting and to avoid rapid 
clearance from the body. Harnessing 
the EPR effect requires an approximate 
particle size between 30 -100 nm [6].  
Nanoparticles (NPs) with sizes between 
15 -100 nm possess a long circulation time 
compared to smaller particles (10-20 nm) 
that are rapidly filtered via the kidneys or 
larger (>150nm) that are uptaken by the 
reticuloendothelial system (RES) [7-9]. 
Nanoparticles of optimal size will eventually 
be uptaken by the liver but they will enjoy 
a long circulation half-life (2-40 h) [10] 
which is critical for the accumulation of the 
nanoparticulate system or the therapeutic 
across the BBB [4]. 
The shape of the particles plays a 
critical role as long axial particles with 
a diameter of ~20 nm and length larger 
than 18µm could remain in circulation 
for longer than 5 days (long enough 
to mechanically hinder uptake into 
macrophages) [11]. Long axial particles as 
peptide nanofibers [3, 4, 12, 13] and carbon 
nanotubes [14] have shown promise in 
delivery of therapies such as peptides 
across an intact BBB enabling 0.4% of the 
intravenous injected dose to reach the 
brain. Between the two technologies, 
peptide nanofibers offer the advantage of 
low toxicity as are able to be completely 
enzymatically metabolised to degradation 
products naturally present within the 
body and the brain parenchyma as well 
as high specificity due to their peptide 
nature [13], and preclinical proof of 
concept in a murine model [3, 12]. 
A hydrophobic particle surface is 
deleterious to a long circulation half-
life and coating of particles with low 
molecular weight surfactants such 
as polysorbate 80 [15] or hydrophilic 
polymers notable polyethylene glycol (5 
KDa), chitosan or albumin can overcome 
this problem [16, 17]. Positively charged 
surfaces promote BBB permeation by 
physical adsorption to the endothelium 
with cationic particles readily taken up 
into the cells at the periphery of tumour 
spheres compared to anionic [18]. Thus, 
the potential to maintain a high plasma 
concentration and interact favourably 
with the blood-tumour interface make 
nanoparticles highly useful for glioma 
targeting. 
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Table 1: Nanoparticle characteristics and their observed impact on tumour localisation
Size (nm) Small Large
<10 nm <20 nm <70 nm <100 nm >150 nm
Rapid glomerular 
filtration
Exit tumour cells 
more easily once 
internalised (↓EPR) 
Improved convective 
flow through tumour 
and normal brain
Permits tumour en-
try via EPR effect
Difficult cell entry 
via endocytosis – 
Clearance by RES
Hydrophobicity Hydrophilic Amphiphilic Hydrophobic
Increased circulation 
half-life
Increased BBB per-
meation
Rapid clearance by 
RES
Surface Charge Cationic Uncharged Anionic
Adsorptive-mediat-
ed BBB trancytosis, 
cell membrane 
disruption at high 
charge
Reduced charge may 
facilitate spread 
through tumour 
ECM
Reduced brain tu-
mour cellular uptake 
in vivo
Key; ECM: Extra-cellular matrix, EPR: Enhanced permeation and retention effect, RES: reticuloendothelial system
Table 2: Clinical trials for GBM nanomedicines
Strategy Title Phase/Status ClinicalTrials.gov 
Identifier
Liposomes 
A study of intraventricular liposomal encapsulated Ara-C (DepoCyt) in 
patients with recurrent GBM
Phase 1/Terminated NCT01044966
Liposomal doxorubicin in treating children with refractory solid 
tumors
Phase I/Completed NCT00019630
Pegylated liposomal doxorubicin and prolonged temozolomide in 
addition to radiotherapy in newly diagnosed GBM
Phase I and II/Completed NCT00944801
Maximum tolerated dose, safety, and efficacy of rhenium 
nanoliposomes in recurrent GBM
Phase I and II/Not yet 
recruiting
NCT01906385
A phase I trial of nanoliposomal CPT-11 (NL CPT-11) in patients with 
recurrent high-grade gliomas
Phase I/Completed NCT00734682
Study of convection-enhanced, image-assisted delivery of 
liposomal-irinotecan in recurrent high grade glioma
Phase I/Enrolling by 
invitation
NCT02022644
An open-label, phase I/IIa, dose escalating study of 2B3-101 in patients 
with solid tumors and brain metastases or recurrent malignant glioma.
Phase I and II/Active, not 
recruiting
NCT01386580
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Table 3: Preclinical studies of nanomericines for glioma
Nanoparticles Drug/Targeting moiety Outcomes Ref
Passive Transport
Lipid Nanocapsules Curcumin Seven days after implantation, rats bearing C6 orthotopic tumours were treated with 
lipid curcumin loaded nanocapsule (1.5mg/kg/day IP, 14 days). A decrease in tumour 
size and a prolonged animal survival (39 days) compared to saline-treated animals (30 
days) was found.
[21]
Polysorbate 80 
coated PBCA 
Nanoparticles
Temozolomide (TMZ) 
or Doxorubicin/[Low 
density lipoprotein (LDL)]
Higher concentrations observed in the liver, spleen, and lungs when TMZ was 
bound with nanoparticles. In the brain, compared with TMZ solution, overcoated 
nanoparticles significantly increased the accumulation of the drug by 2.29-fold (1.10 ± 
0.19 µg/g versus 0.48 ± 0.11 µg/g, IV dose 10mg/kg Temozolomide). Increase survival in 
101/8 rat models after IV admistration at 2,5,8 days after implantation of doxorubicin 
overcoated nanoparticles (2.5mg/kg, 35 days) compared to saline, doxorubicin alone, 
doxorobucin PBCA nanoparticles (24.5, 27, 35 days respectively). 
[22]
Adsorptive Endocytosis
Wheat germ 
agglutinin (WGA) 
- and tamoxifen-
coupled Liposomes
Daunorubicin and 
quinacrine (Tamoxifen 
inhibits ABC transporters)
In vitro, multifunctional liposomes (uncharged, ~100 nm) were able to permeate across 
the BBB via adsorptive endocytosis. In a GSC ICR murine model, the survival ranges 
of mice treated with the saline, daunorubicin and quinacrine liposomes or WGA-
tamoxifen-liposomes was enhanced from 26, 30.83 to 36.33 days respectively when a 
dose of 5mg/kg was injected IV on days 10, 12, 14, and 12 post tumour implantation.
[20]
Active Transport – Lipidic Nanomedicines
Cationic Liposomes Doxorubicin/Lactoferrin Rats bearing C6 orthotopic tumours were injected IV with 3 doses of 2.5 mg/kg 
on days 3, 6, and 12 post tumour implantation. Treatment resulted in prolongation 
of survival between lactoferrin-targeted liposomes (96.13 days) and doxorubicin 
liposomes (56.87 liposomes). 
[23]
T7- and  
TAT- Liposomes
Doxorubicin/Transferrin BALB/c bearing C6 orthotopic spheroid tumours injected IV with 3 doses of 2.5 mg/
kg on days 8, 11, and 14 post tumour implantation showed an enhanced median survival 
time (43 days) compared to saline group (17 days).
[24]
TAT-cholesterol-
conjugated 
Liposomes
Doxorubicin/Transferrin Rats bearing C6 orthotopic tumours were injected IV with 3 doses of 2.5 mg/kg on 
days 3, 6, and 12 post tumour implantation. Treatment resulted in prolongation of 
survival between lactoferrin-targeted liposomes (79.4 days) and doxorubicin liposomes 
(57.50 liposomes).
[25]
p-aminophenyl-α-D-
manno-pyranoside 
and Tf-coupled 
Liposomes
Daunarobucin/
Transferrin and GLUT-1
Increased transport ratio up to 24.9% across in vitro BBB model. Rats bearing C6 
orthotopic tumours were injected IV with 3 doses of 5 mg/kg on days 8, 10, and 12 
post tumour implantation. Median survival time of tumour bearing rats (22 days) was 
longer than saline 13 days) and daunorucin-liposomes (18 days).
[26]
Tf- and tamoxifen-
coupled Liposomes
Epirubicin (Tamoxifen 
inhibits ABC 
transporters)/Transferrin
Rats bearing C6 orthotopic tumours were injected IV with 3 doses of 5 mg/kg on days 
7, 9, and 11 post tumour implantation. Treatment resulted in a significant reduction 
in tumour volume and prolongation of survival between Tf-tamoxifen liposomes (23 
days), epirubicin liposomes (17 days), epirubicin alone (15 days) and saline (12 days). 
[27]
Octa-arginine (R8)  
and RGD-coupled 
Liposomes
Paclitaxel/αvβ3 integrin BALB/c mice were IV injected with saline, free PTX, PTX-PEG-liposomes, PTX-R8-RGD-
liposomes, PTX-R8-liposomes and PTX-RGD-liposomes (3 mg/kg) at 4, 6, 8, 10, 12 and 14 
days after implantation and enhanced survival was observed in PTX-R8-RGD-liposomes 
26,32,39,48,36,38 respectively). 
[28]
p-aminophenyl-α-D-
mannopyranoside-D-
α-tocopheryl- and 
dequalinium-coupled 
Liposomes
Paclitaxel and 
artemether/GLUT-1 (& 
adsorptive endocytosis)
Induction of apoptosis in brain cancer cells and brain cancer stem cells by activating 
apoptotic enzymes and pro-apoptotic proteins and inhibiting anti-apoptotic proteins. 
The median survival time of rats bearing C6 orthotopic tumours treated with the 
functional targeting paclitaxel plus artemether liposomes (35 days) was significantly 
longer than that of rats treated with physiological saline (17 days), taxol (22 days), 
paclitaxel liposomes (24 days), paclitaxel plus artemether liposomes (25 days), MAN-
targeting paclitaxel plus artemether liposomes (28 days), and DQA-mediated targeting 
paclitaxel plus artemether liposomes (29 days), respectively.
[29]
Angiopep-2-cationic 
Liposomes
Paclitaxel and pEGFP-
hTRAIL gene /LDL
Targeting delivery system improved uptake and gene expression not only in U87 MG 
cells. Median survival time of U87MG- tumour-bearing BALB/c mice treated with 
liposomes was 69.5 days, significantly longer than other groups (50 µg pEGFP-hTRAIL 
and 5 µg PTX per mouse), even longer than the TMZ positive control group (47 days, 
50mg/kg) (animals dosed at 7,9,11,13 days).
[30]
Angiopep-2 and 
neuropilin-1-coupled 
Liposomes
Docetaxel (DTX) and 
VEGF siRNA/LDL & 
Neuropilin-1 receptor
The dual peptide-modified liposomes showed superiority in anti-tumour efficacy, 
combination of anti-angiogenesis by VEGF siRNA and apoptosis effects by DTX, after 
both intratumour and system application against mice with U87 MG tumours, and the 
treatment did not activate system-associated toxicity or the innate immune response.
[31]
Anti-EGFR-coupled 
Liposomes
Sodium borocaptate/ 
EGFR
In an animal model of glioma, both liposomes and sodium borocaptate were only 
observed in the tumour. The therapeutic effect was confirmed by inductively coupled 
plasma-atomic emission spectrometry both in vitro and in vivo.
[32]
Active Transport – Polymeric Nanomedicines
Tf-and-cyclo-[Arg-
Gly-Asp-dPhe-Lys] 
(c[RGDFK]) – 
paclitaxel conjugated 
Micelle (TRPM)
Paclitaxel (PTX)/
Transferrin 
TRPM enhanced  mean survival time of mice bearing intracranial U87 MG glioma 
treated with TRPM (42.8 days) than those treated with Tf modified PTX loaded micelle 
(39.5 days), PTX loaded micelle (34.8 days), Taxol© (33.6 days), and saline (34.5 days)
[33]
Angiopep-coupled 
poly(ethylene glycol)-
poly(caprolactone) 
Nanoparticles
Paclitaxel (PTX)/LDL Enhanced accumulation of ANG-NP in the glioma bed and infiltrating margin of 
intracranial U87 MG glioma tumour-bearing in vivo model were observed by real time 
fluorescence image.
[34]
Aptamer (AP) 
AS1411-coupled 
poly(ethylene 
glycol)-poly(lactic-
co-glycolide) 
Nanoparticles
Paclitaxel (PTX)/ 
Nucleolin
Prolonged circulation and enhanced drug accumulation at the tumour site in vivo. 
Prolonged circulation and enhanced PTX accumulation at the tumor site was achieved 
for Ap-PTX-NP, resulting in prolonged animal survival on rats bearing intracranial C6 
gliomas when compared with PTX-NP and Taxol® (3 mg/kg, every 2 days for seven 
consecutive injections until the 20th day).
[35]
APTEDB-conjugated 
poly(ethylene 
glycol)-poly(lactic 
acid) Nanoparticles
– /Extra-domain of 
tumour-associated 
fibronectinfibronectin 
extra domain B (EDB)
APTEDB-NP-PTX exhibited improved anti-glioma efficacy over unmodified 
nanoparticles and Taxol® in both subcutaneous and intracranial U87MG xenograft 
models and enhanced the medium survival time of the mice treated with saline, 
Taxol®, NP-PTX and APT-NP-PTX was 19, 24, 31, 41 days, respectively.
[36]
tLYP-1-functionalized 
poly(ethylene 
glycol)-poly(lactic 
acid) Nanoparticles
Paclitaxel/Neuropilin Survival of BALB/c mice bearing intracranial U87MG glioma was enhanced (Mice 
treated with saline, Taxol®, NP-PTX and tLyp-1-NP-PTX survived for 18, 23, 28, 37 days 
respectively). Dose was set at 5mg/kg every 3 days over 2 weeks. 
[37]
F3-functionalized 
poly(ethylene 
glycol)-poly(lactic-
co-glycolide acid) 
Nanoparticles
Paclitaxel/ Nucleolin Survival after IV administration of four groups (saline, NP, F3-NP were injected 
into mice bearing intracranial C6 glioma at the dose of PTX 5 mg/kg, and the 
co-adminstration peptide tLyp-1 were given at the dose of 4 µM/kg 5 min after the 
NPs injection).  Following co-administration with tLyp-1 peptide, F3-nanoparticles 
displayed enhanced accumulation at the tumour site and promoted longest survival in 
mice [Saline: 9 days, Taxol: 24 days, NP: 27 days, F3-NP: 32 days, Np and tLYP-1: 31 days, 
F3-NP and tLyp-1: 42 days)]
[38]
iNGR-conjugated 
poly(ethylene 
glycol)-poly(D,L-
lactic-co-glycolic 
acid) Nanoparticles
Paclitaxel/ Neuropilin-1 
and Aminopeptidase N
iNGR-nanoparticles exhibits significantly enhanced cellular uptake in human umbilical 
vein endothelial cells, improves the anti-proliferation and anti-tube formation abilities 
of paclitaxel in vitro. In vivo, it was verified an improved anti-angiogenesis activity and 
significantly prolonged survival time in mice bearing intracranial glioma (42.5 days).
[39]
MT1-AF7p-coupled- 
poly(ethylene 
glycol)-poly(D,L-
lactic-co-glycolic 
acid) Nanoparticles
Paclitaxel/ Membrane 
type-1 matrix 
metalloproteinase
The median survival of mice bearing C6 glioma treated with MT1-NP-PTX and iRGD 
(60 days) was significantly longer than those of mice treated with physiological saline, 
Taxol®, NP-PTX, NP-PTX and iRGD, MT1-NP-PTX (21, 24,32, 40, 48 days, respectively) [PTX 
dose 5 mg/kg, iRGD dose 4 μmol/kg, animals dosed at day 7, 10, 13, 16, 19 and 22 post 
implantation].
[40]
Key: APT: Aptamer peptide or aptide, APTEDB: aptide specific for extra-domain of tumour-associated fibronectin B, BBB: blood-brain-barrier, 
EGFR: epidermal growth factor receptor, F3 peptide: Cys-Lys-Asp-Glu-Pro-Gln-Arg-Arg-Ser-Ala-Arg-Lys-Ser-Ala-Lys-Pro-Ala-Pro-Pro-Lys-Pro-Glu-
Pro-Lys-Pro-Lys-Lys.Ala-Pro-Ala-Lys-Lys, G-22-MAb: anti-glioma monoclonal antibody, iNGR peptide (Cys-Arg-Asn-Gly-Asn-Gly-Pro-Asp-Cys), 
MT1-AF7p : Phase display peptide (His-Trp-Lys-His-Lys-His-Asn-Thr-Lys-Thr-Phe-Leu) with high specificity to MT1-MMP (Membrane type-1 matrix 
metalloproteinase), Neuropilin: a modular transmembrane protein identified as a receptor for various forms and isoforms of VEGF, pEGFP-hTRAIL: 
human tumour necrosis factor-related apoptosis-inducing ligand, PTX: Paclitaxel, RGD: Arg-Gly-Asp, GLUT-1: glucose transporter-1,T7: His-Ala-Ile-
Ty-Pro-Arg-His, siRNA: small interfering RNA, NP: nanoparticles, TAT: cell penetrating peptide (Ala-Tyr-Gly-Arg-Lys-Lys-Tyr-Tyr-Gln-Tyr-Tyr-Tyr), Tf: 
transferrin, tLyp-1: a truncated form of Lyp-1 (Cys-Gly-Asn-Lys-Arg-Thr-Arg), TMZ: Temozolomide, VEGF: Vascular endothelial growth factor.
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In a preclinical phase, the most 
significant survival benefits in orthotopic 
animal models have been achieved 
with lipidic or other polymeric 
nanomedines (Table 3) even if a wide 
variety of particles (dendrimers, peptide 
nanofibers, carbon nanotubes, and 
solid lipid nanoparticles) are under 
investigation.
Liposomal Nanomedicines
Only liposomal particles (spherical 
vesicles composed of a lamellar phase 
lipid bilayer) are undergoing clinical 
trials for GBM, but the outcomes of 
these studies are still awaited (Table 
2). The faster progression of liposomal 
formulations of chemotherapies 
to the clinic can be attributed to 
the fabrication of liposomes using 
GRAS excipients and that liposomal 
nanomedicines loaded with doxorubicin, 
vincristine, daunorubicin, or cytarabine 
(Depocyt®) for the treatment of 
systemic cancers have been approved 
by the FDA (Doxil® for Kaposi’s sarcoma 
approved in 1995, Caelyx® for metastatic 
breast cancer approved by EMA in 1996 
and Lipodox® pegylated doxorubicin 
liposomes for metastatic ovarian cancer 
approved by the FDA in 2013) [19].  
Although, currently several intravenous 
nano-enabled chemotherapies are 
approved for various cancer indications, 
so far none is approved for a brain 
tumour indication. Depocyt® underwent 
phase I and II trials for central nervous 
system metastases from melanoma 
and breast cancer (Table 2), however, 
the results of this study are not yet 
available. 
Drugs can be loaded to the particle 
surface, intercalated within the lipidic 
bilayer and also within the core of 
liposomes. For adequate brain delivery, 
liposomal formulations need to be 
pegylated (PEG chain length 2-5 kDa 
in length) to confer adequate steric 
hindrance and stabilisation of the 
liposome, mask the surface charge 
and reduce opsonisation enhancing 
their circulation half-life.  Similarly, 
delivery of liposomes loaded with 
chemotherapies for delivery to the 
central nervous system necessitates 
a cationic charge conferred by the 
fabrication of liposomes using cationic 
phospholipids such as 1,2-Distearoyl-
sn-glycero-3-phosphoethanolamine 
(DSPE) via adsorptive endocytosis [20]. 
However, if this pathway is not utilised, 
liposomes are able to permeate the BBB 
only when decorated with a ligand for a 
receptor expressed on the BBB to enable 
the endocytosis of the particle (Table 
3). In some cases, dual functionalization 
may also be required to enable targeting 
of the liposomes to the glioma such as 
transferrin, insulin, folic acid, neuropilin 
and epidermal growth receptor. (Table 3). 
Polymeric Nanomedicines
Passive transport however, has been 
achieved mainly only for polymeric 
nanoparticles loaded with drugs on the 
surface or core of the particle (Table 
3). Drug loading is in majority of the 
cases higher in polymeric nanoparticles 
compared to lipidic, for hydrophobic 
poorly soluble drugs, as well as for 
hydrophilic biomacromolecules and 
gene therapies. These carriers also show 
a higher stability including stability upon 
dilution in biological fluids and against 
enzymatic metabolism. 
While polymeric nanoparticles are 
typically thought of as passive smart 
delivery vehicles, they can also be 
engineered to actively target tumours 
targeting a number of receptors 
either to gain entry across the BBB 
or overexpressed on GBM cells with 
similar chemistries and with enhanced 
possibilities to those relevant to lipidic 
nanoparticles. There has been an 
increased number of successful animal 
studies in mice and rats over the last 
decade resulting in an enhanced median 
survival increase of ideally ~20 days 
[41]. Care must be taken in comparing 
the results of these studies, however, 
as different animal models have been 
used and only a few studies were 
complemented by pharmacokinetic 
studies. Xenografts derived from 
neurosphere cultures and from biopsy 
spheroid cultures as well as several 
genetically engineered mouse models 
more faithfully reflect the genotypic 
and phenotypic changes seen in human 
GBMs and recapitulate the infiltrative 
growth of human gliomas [42], compared 
to xenografts from chemically induced 
models as well as normal glioma cell 
lines grown in serum-supplemented 
media. Delays in translation of polymeric 
nanoparticles into the clinic arise 
from the need of rigorous testing of 
short- and long-term particle safety 
(including immunogenicity) and more 
detailed study of particle biodistribution 
in large animal models [43] as well as 
development of protocols permeating 
the scale-up of the production of 
loaded and functionalised nanoparticles 
maintaining target molecule attachment 
under conditions of clinical-grade 
sterility.
Toward a cure – 
Nanotechnology in the 
operating room and in the 
clinic
Nano-enabled platforms, rather 
than simply allowing treatment 
through a single modality, offer the 
realistic opportunity for multi-modal 
treatment, employing many useful 
approaches simultaneously. Thus, 
a number of therapeutic strategies 
can be incorporated via a common 
nanoscale agent for targeted delivery 
or even theranostic applications. Thus, 
a hypothetical particle can be injected 
intraoperatively after resection carrying 
iron oxide for example for identification 
of the margins of the tumour bed under 
a magnetic field [44, 45], while also 
carrying one or more targeting agents 
to promote internalisation past the 
BBB and to the tumour cell nucleus 
if needed. After surgery, nanoparticle 
enhanced ionising-beam therapy could 
be chosen acting synergistically with 
the chemotherapeutic drugs loaded 
or conjugated within the particle. If 
resection is not indicated, due to the 
deep intracerebral localisation of the 
tumour, CED (convection enhanced 
delivery)  of the nanoparticulate 
formulation possibly taking place at the 
same time as stereotactic biopsy can be 
an option. The latter would be followed 
by imaging to ensure absence of off-
target diffusion (e.g. to the brainstem 
or near large cerebral vasculature). 
Molecular engineering allows the choice 
of simultaneous treatment strategies 
acting synergistically towards tumour 
cell eradication at the edge of the 
tumour and beyond. Such combined 
therapeutic strategies will likely be 
translated for clinical testing within the 
next decade based on existing clinical 
and preclinical trials. Thus, rather 
than a substitute for surgical therapy, 
nanomedicines will provide an adjunct 
to modern surgical strategies, improving 
the extent of resection, working non-
invasively towards tumour eradication of 
remaining tumour cells and enable the 
targeting of biomolecular mechanisms 
that make GBM challenging to treat. 
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